Nuvectis Pharma, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Nuvectis is a clinical-stage oncology biopharmaceutical company developing NXP800 and NXP900. It has no approved products and has generated no revenue.
Financial highlights
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $4.486m | $4.520m | $11.115m | $8.830m |
| General and administrative expense | $1.672m | $1.418m | $4.916m | $3.626m |
| Operating loss | $6.158m | $5.938m | $16.031m | $12.456m |
| Net loss | $5.881m | $5.877m | $15.638m | $12.389m |
| Basic and diluted loss per share | $0.37 | $0.42 | $1.02 | $1.03 |
At September 30, 2023, cash and cash equivalents were $22.059m, total current assets were $22.262m, current liabilities were $5.576m, and stockholders’ equity was $16.686m. The filing reports no debt. Nine-month operating cash use was $12.104m; financing provided $14.170m; investing cash flows were zero. No operating margin is meaningful because the company had no revenue.
Changes and notable items
- Q3 net loss was nearly unchanged year over year. R&D spending was broadly flat as higher manufacturing and clinical costs were offset by lower license fees; G&A rose, mainly from public-company professional and consulting costs.
- For the first nine months, net loss increased $3.249m. R&D rose $2.285m, primarily from manufacturing, personnel and clinical costs; G&A rose $1.290m, largely from professional services and compensation.
- Cash increased $2.066m from year-end 2022, supported by equity-related financing. The company received $14.170m net financing cash, including proceeds from warrant and preferred investment option exercises and ATM sales. It reported 17,309,911 shares outstanding at September 30, 2023.
- Share-based compensation was $3.485m for the nine months, versus $1.225m in the prior-year period; this noncash expense is included in operating costs.
Outlook, risks and contingencies
- Management said cash at September 30, 2023 was expected to fund planned operations for at least 12 months following issuance of the financial statements. This estimate depends on assumptions and the company expects to need additional capital to complete development and clinical trials.
- Management expects expenses to increase as clinical and preclinical programs advance, including manufacturing, trial, staffing and public-company costs. No specific revenue, earnings or cash-flow guidance was provided.
- NXP800’s Phase 1b expansion in platinum-resistant, ARID1a-mutated ovarian cancer began in Q2 2023; NXP800 received Orphan Drug Designation for cholangiocarcinoma in August 2023. NXP900’s Phase 1 study began in September 2023 after FDA IND clearance in May.
- Potential license milestones and royalties are contingent and were not accrued. Disclosed potential obligations include up to $22.0m in NXP800 pre-approval milestones and up to $45.0m in NXP900 pre-approval milestones, plus further regulatory and commercial milestones and royalties. The filing also describes up to $0.2m of remaining ICR research support expected to be expensed in Q4 2023.
- The company warned that inability to obtain adequate financing could require it to delay, reduce or terminate development or other operations. It reported no contingent liabilities, no material legal matters, and no material changes to previously disclosed risk factors.
Key facts investors should verify
- Whether cash burn and updated trial/manufacturing plans remain consistent with the stated 12-month runway, and when additional financing may be needed.
- Clinical progress, safety and efficacy data, enrollment, and regulatory milestones for both NXP800 and NXP900.
- Future equity issuance and dilution, including use of the ATM and remaining exercisable warrants or investment options.
- Timing and potential financial impact of license research commitments, milestones and royalties as programs advance.